Immune cell combo shows promise in Hard-to-Treat head and neck cancer
NCT ID NCT04290546
First seen Feb 28, 2026 · Last updated Apr 30, 2026 · Updated 10 times
Summary
This early-phase trial tested a combination of immune-boosting drugs and specially trained natural killer (NK) cells in 11 people with advanced head and neck cancer that had returned or spread. The goal was to see if the treatment was safe and could shrink tumors. While not a cure, this approach aims to help the body fight the cancer more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.